- On December 16, Fosun and BioNTech announced the formation of a strategic alliance for marketing BioNtech's Covid 19-vaccine in China, Hong Kong, Taiwan and Macao.
- Under the agreement, BioNTech has committed to supply at least 100 million doses to Fosun in 2021, with preparations reportedly underway for Fosun to manufacture the BNT162b2 vaccine in China.
- Fosun said it will be entitled to 60-65% of annual gross profit from sales.
- Fosun completed India's biggest Pharma IPO during November with the listing of Gland Pharma Ltd.
For further details see:
Fosun Providing BioNtech's Covid 19-Vaccine The Keys To The East